ST. LOUIS, March 22 /PRNewswire-FirstCall/ -- Sigma-RBI, a division of Sigma-Aldrich , a $1.4 billion Life Science and High Technology Company, has released the most comprehensive compilation of current information on obesity and diabetes in its new Obesity and Diabetes Brochure.
The brochure reviews reasons for increases in obesity and diabetes, as well as the mechanisms of energy homeostasis, the effect of peptides, cytokines and biogenic amines on food intake, the insulin signaling pathway, and the roles of protein tyrosine phosphatases, peroxisome proliferator- activated receptors and JNK kinases in diabetes.
Over 550 Sigma-Aldrich products are highlighted, including interleukin proteins and antibodies, leptin peptides and antibodies, orexins, neurotrophic factors, and products for lipid signaling, protein phosphorylation and gene regulation.
"This brochure is an invaluable tool for anyone researching obesity and diabetes," said Julie Coughlan, Product Manager, Cell Signaling. "The comprehensive information and product list is based on the most current research available."
Obesity has reached epidemic proportions in many countries in the developed world. In the US, it is estimated that over 60% of adults are overweight and over 30% are obese. Worldwide the prevalence of obesity has increased over 75% since 1980. In addition to its effects on health, obesity imposes a significant financial burden on society in terms of medical expenses.
Diabetes is a medical condition characterized by high blood glucose levels and caused by a decrease in insulin secretion and action. It can be autoimmune in nature (type 1, or juvenile), or brought on by altered insulin secretion or insulin resistance (type 2, or age-onset). Type 2 diabetes accounts for 90-95% of all cases and exhibits a worldwide prevalence of 150 million that is expected to increase to 225 million by 2010 and 300 million by 2025. Even more disturbing is the increase in the number of children and adolescents diagnosed with type 2 diabetes, which historically had been present only in adults. Due to these statistics, obesity and diabetes have become a major focus of researchers worldwide.
For more information please visit http://sigma-aldrich.com/obesitybrochure .
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 35 countries and has over 6,500 employees providing excellent service worldwide. We are committed to the success of our Customers, Employees and Shareholders through leadership in Life Science, High Technology and Service.
Photo: http://www.newscom.com/cgi-bin/prnh/20050215/CGSIGMAALLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comSigma-RBICONTACT: Joan Suda, +1-314-286-7626, or Lisa Prostak, +1-508-651-8151,ext. 269, both of Sigma-Aldrich